Assessment Of Comparative Immunogenicity In Biosimilar Development: Immunogenicity And Pharmacokinetics Following A Single Dose Of M923, A Proposed Biosimilar For Reference Adalimumab (Humira (R)), Compared With Us- And Eu-Sourced Reference Adalimumab In Healthy Subjects

ARTHRITIS & RHEUMATOLOGY(2016)

引用 0|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要